New Test Predicts Breast Cancer Recurrence and Radiation Therapy Benefit

Researchers from the United States and Sweden published a study in Breast Cancer Research demonstrating that the new Aida test, can predict 10-year recurrence risk and radiation therapy benefit for patients with early-stage invasive breast cancer.

The study, which followed 922 patients for a median of 10 years, marks a shift toward using biological markers rather than just clinical features to guide treatment decisions after breast-conserving surgery.

Main data that support the findings

The study findings indicate that the Aida test provides both prognostic and predictive information by using a Decision Score (DS) to predict the 10-year risk of locoregional recurrence and a Radiation Resistance Index (RRI) to predict how a tumor will respond to radiation.

Investigators found that as the continuous Decision Score increased, the risk of the cancer returning also increased. Patients in the DS Elevated Risk group had a 24% risk of recurrence at 10 years without radiation, compared to a 7% risk for those in the DS Low Risk group.

The test identified a low-risk group of patients who did not have a statistically significant benefit from radiation therapy. In contrast, radiation was associated with a decreased risk of recurrence for patients with an elevated Decision Score and a lower Radiation Resistance Index. However, for patients with both a high Decision Score and a high Radiation Resistance Index, radiation was not associated with a statistically significant reduction in recurrence risk.

"Aida is the first and only test designed to provide both prognostic assessment of locoregional recurrence risk and predictive insight into radiation therapy benefit," said Dr. Naamit Gerber, radiation oncologist at NYU Langone Health's Perlmutter Cancer Center and co-author of the study, in a news release.

Trial details

The retrospective multi-institutional study evaluated 922 patients with hormone receptor-positive (HR+), HER2-negative invasive breast cancer who were treated with breast-conserving surgery, with and without adjuvant radiation. The research took place across four academic and clinical centers in the United States and Sweden.

The test integrates targeted NextGen RNA expression with multiplex protein biomarker expression and spatial biology. According to Troy Bremer, Chief Scientific Officer of PreludeDx, this multi-omic platform captures dimensions of tumor biology that cannot be assessed through clinicopathologic features alone.

This new tool builds on the technology used in DCISionRT, a test for patients with ductal carcinoma in situ (DCIS). While DCISionRT focuses on cancerous cells that have not spread into surrounding tissue, Aida extends this biological precision into early-stage invasive breast cancer.

Safety

The study suggests that the Aida test may enable clinicians to safely escalate or de-escalate therapy based on molecular biology. By identifying patients who do not derive a significant benefit from radiation therapy, the test supports more informed, shared decision-making regarding treatment intensity.

The researchers noted that because breast cancer care is shifting toward personalization, aligning treatment with individual patient risk is essential when locoregional recurrence rates are low. While the publication validates the strength of the multi-omic platform, further clinical validation studies are in process and prospective validation studies are being planned to establish the role of the test in clinical practice.

"The publication of this study represents an important milestone not only for Aida, but for PreludeDx as a whole," said Dan Forche, President and CEO of PreludeDx, in the news release. "With DCISionRT transforming radiation decision-making in DCIS and AidaBreast extending biologic precision into early-stage invasive breast cancer, PreludeDx is uniquely positioned to lead the evolution of personalized radiation therapy decisions. Our portfolio reflects a long-term commitment to delivering clinically actionable biology across the continuum of early-stage breast cancer care."

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.